Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy
Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy
Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Feasibility Study of Intraoperative Imaging in Breast Cancer
Feasibility of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Feasibility Study of Intraoperative Imaging in Breast Cancer
Feasibility of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Marin General Hospital
mi
from
Greenbrae, CA
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Marin General Hospital
mi
from
Greenbrae, CA
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital, San Jose
mi
from
San Jose, CA
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital, San Jose
mi
from
San Jose, CA
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Broward Health Medical Center
mi
from
Fort Lauderdale, FL
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Broward Health Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Faulkner Hospital
mi
from
Boston, MA
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
Presbyterian Medical Center
mi
from
Charlotte, NC
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction
AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND-II)
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors
Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors
Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
[18F]ISO-1 PET/CT in Breast Cancer
Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Hospital
mi
from
Philadelphia, PA
[18F]ISO-1 PET/CT in Breast Cancer
Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial)
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial)
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Investigational Site
mi
from
Brussels,
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
The West Clinic, PC
mi
from
Memphis, TN
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Duarte, CA
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Duarte, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Santa Barbara, CA
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Denver, CO
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Denver, CO
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Miami, FL
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
West Palm Beach, FL
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Boston, MA
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 2
mi
from
Boston, MA
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 2
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Minneapolis, MN
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Saint Louis, MO
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Lebanon, NH
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
New York, NY
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #2
mi
from
New York, NY
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #2
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Chattanooga, TN
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Nashville, TN
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Nashville, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Austin, TX
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Fort Worth, TX
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
San Antonio, TX
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #2
mi
from
San Antonio, TX
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #2
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Sherman, TX
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Sherman, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Salem, VA
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Salem, VA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Winchester, VA
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Winchester, VA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Madison, WI
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Madison, WI
Click here to add this to my saved trials
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated:  12/31/1969
Arizona Cancer Center
mi
from
Tucson, AZ
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated: 12/31/1969
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute
mi
from
Stanford, CA
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospital and Clinics
mi
from
Miami, FL
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospital and Clinics
mi
from
Miami, FL
Click here to add this to my saved trials